Rihe Liu, PhD
School of Pharmacy
Core Technology and Enabling Features
Universal targeting system for immunotherapy; General Antigen Receptor (GAR) as next generation cancer immunothearpy.
NEO: Delaware LLC
Andrew Kant, NEO, email@example.com
Panacise Bio LLC is developing a next generation cancer immunotherapy platform (GAR-T) aimed at providing a self-assembling, universal and versatile approach to treating cancer.
PCT (PCT/US2014/058257) Methods and compositions for self-assembly system of nanoparticles and microparticles for multi-targeting specificity
NEO, STTR application submitted
Technology and Product Development
Application identified as immunotherapeutic agents which combines advantages of CAR-T cell therapy and immune checkpoint inhibition. Pilot study scheduled for Feb 2016.